Does PRME pay a dividend and is it safe?

Prime Medicine Inc. (PRME) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PRME / dividends

MGTX (20) GLUE (25) ODTX (46) SANA (33) ⌘ Pro Terminal →

Prime Medicine Inc. (PRME) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.44 -5.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.38

Prime Medicine Inc. (PRME) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $856.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRME Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Prime Medicine Inc. (NASDAQ: PRME) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.44 (-5.93% 1D, market cap $856.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRME ranks #789 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRME compare to MGTX and GLUE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PRME carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $911.4M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M). Among the 5-stock peer group, PRME leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRME?

▼

Per PRME's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894562), Prime Medicine Inc. generated $4.6M in revenue (+55.3% YoY), -$201.1M in net income, and -$167.1M in free cash flow against $342.7M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.38 (-1.26%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRME)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY PRME SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (53% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 58.5 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.32+18.1% Next Q

Q2 (-2Q)

Grade E$3.92+11% Next Q

Q3 (-1Q)

Grade E$4.35+2.1% Next Q

Current

Grade E$4.44-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRME Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRME currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.60) and Max Pain ($4.66) forces dealer call-delta covering toward $6.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRME• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRME Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRME)

✓Walkthrough of PRME's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRME // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.95%▲ ASCENDING CHANNEL

2026-11-03O $5.24H $5.24L $4.44C $4.44VOL 6.57M

RES: $5.95SUP: $2.80SMA50: $3.60SMA200: $3.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRME Butterfly Map → + Track PRME →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +55.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRME today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRME. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRME today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRME)

Health Care Rank #789 of 1015 ⚔️ MGTX vs PRME Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRME vs. MGTX, GLUE, ODTX, SANA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Prime Medicine Inc. (PRME) ranks #789 by composite RQD confidence (30/100, grade E) and #378 by equity capitalization ($856.1M). Within this direct 5-issuer industry benchmark cohort, PRME leads on earnings valuation at N/A trailing P/E, while PRME leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PRME at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRME ACTIVE Prime Medicine Inc.	E	30/100	—	—	-35.0%	-5.93%	$856.1M	Benchmark Subject
MGTX MeiraGTx Holdings plc	E	20/100	—	—	-35.0%	-1.79%	$911.4M	/mgtx-vs-prme →
GLUE Monte Rosa Therapeutics Inc.	E	25/100	—	—	-35.0%	-1.21%	$918.0M	/glue-vs-prme →
ODTX Odyssey Therapeutics Inc.	D	46/100	—	—	—	-0.05%	$939.1M	/odtx-vs-prme →
SANA Sana Biotechnology Inc.	E	33/100	—	—	-35.0%	-6.61%	$769.4M	/sana-vs-prme →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894562 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prime Medicine Inc. (PRME) reported GAAP revenue of $4.6M (+55.3% vs. FY2024 revenue of $3.0M , and -99.2% cumulative change since FY2023) , GAAP net income of -$201.1M, operating cash flow of -$162.6M, and free cash flow of -$167.1M (-28.4% YoY). On the balance sheet, PRME closed FY2025 with $342.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.6M	-$201.1M	-$162.6M	-$167.1M	$342.7M	—
FY2024 (FY)	2024-12-31	$3.0M	-$195.9M	-$122.9M	-$130.2M	$297.5M	—
FY2023 (FY)	2023-12-31	$573.4M	-$198.1M	-$165.4M	-$165.4M	—	—

3. PRME Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRME compare to MGTX and GLUE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRME?

Where is PRME trading relative to its 50-day, 200-day, and 52-week technical levels?

PRME last traded at $4.44 (-5.93% on volume of 4,124,841 shares), positioning the stock +23.33% above its 50-day simple moving average ($3.60) and +26.86% above its 200-day simple moving average ($3.50). Across its 52-week range of $2.67 to $5.91, PRME sits at the 54.6% percentile with a 14-day RSI of 58.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.88 to $5.00).

Direct Sub-Reports: PRME RQD Cockpit PRME 12M Forecast PRME Earnings & Move PRME Dividends & DRIP PRME Insiders & 13F PRME Whale Options PRME Profit Sankey PRME News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

PRME — Prime Medicine Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Prime Medicine Inc. (PRME) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.44 (-5.93% 1D, market capitalization $856.1M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -17.58%.
Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Prime Medicine Inc. (PRME) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $1.0B. Reported FY 2025 revenue was $4.6M against an operating loss of -$208.3M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Prime Medicine Inc. (PRME) reported $4.6M in annual revenue (up from $3.0M in FY2024, +55.3% YoY) and -$201.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($573.4M revenue, -$198.1M net income) through FY2025, PRME scaled operating cash flow to -$162.6M and free cash flow to -$167.1M, backed by $342.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 30/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -17.58% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $2.67 – $5.91 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated dependencies. A prospective investor should note that this absence is itself a data limitation rather than evidence of independence, since the graph contains no entries. Sector context is limited to the Health Care / Biological Products classification and the beta of 1.0 per the market data.

Key Question #1: Can PRME sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.6M and free cash flow of -$167.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is PRME's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRME Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prime Medicine Inc. (PRME) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRME Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

Yahoo Finance report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Prime Medicine stock rating maintained at Market Outperform by Citizens

Investing.com report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins

Timothy Sykes report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 1d ago

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why

MarketBeat report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

Yahoo Finance report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 1d ago

Prime Medicine (PRME) Stock Price, Chart & Analysis

www.debelegger.nl report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Companies Like Prime Medicine (NASDAQ:PRME) Could Be Quite Risky

Simply Wall St report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Prime Medicine (NASDAQ:PRME) Stock Jumps 3.5% - Here's Why

MarketBeat report covering Prime Medicine Inc. (PRME) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRME Bull vs. Bear Conversation Board — What's Your Call at $4.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRME 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $5.43 (+15.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 17/20 in the RQD rating, the strongest pillar, alongside a recent rally of nea

Institutional accumulation and options positioning score 17/20 in the RQD rating, the strongest pillar, alongside a recent rally of nearly 26% in a month.. When you look under the hood at PRME, Fundamental Cash Engine is 2/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $5.91. My 12M target is $5.43.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.01 (-15.0%)

Spot @ $4.72

Operating margin of -60%, FCF yield of -17.58%, Altman Z of 0.2, and cash falling from $182.5M to $63.0M leave the company with weak ca

Operating margin of -60%, FCF yield of -17.58%, Altman Z of 0.2, and cash falling from $182.5M to $63.0M leave the company with weak cash generation and elevated distress risk.. Look at the math on PRME: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $4.15 before getting long.